Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other Events

Item 8.01 Other Events.

On June26, 2017, Trovagene,Inc. issued a press release announcing
that the U.S. Patent and Trademark Office, and separately, the
European Patent Office, have allowed claims for Patent
Application 13/959739 and Patent Application EP10184598.0,
respectively, entitled Nucleophosmin Protein (NPM) Mutants,
Corresponding Gene Sequences and Uses Thereof. A copy of the
press release is furnished as Exhibit99.1 to this Form8-K.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits.

Trovagene, Inc. Exhibit
EX-99.1 2 a17-15737_1ex99d1.htm EX-99.1 Exhibit 99.1     Trovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia   SAN DIEGO,…
To view the full exhibit click here
About Trovagene, Inc. (NASDAQ:TROV)

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Trovagene, Inc. (NASDAQ:TROV) Recent Trading Information

Trovagene, Inc. (NASDAQ:TROV) closed its last trading session down -0.14 at 1.00 with 5,255,079 shares trading hands.